Organosyn Limited Llc Pharmaceutical Import Profile — Poland (DGFT 2022–2026)

Name: Organosyn Limited Llc Pharmaceutical Import Records from India — 5 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Organosyn Limited Llc — Pharmaceutical Importer Profile (2026) | 5 Products, $1.9M Trade | TransData Nexus

Organosyn Limited Llc

Pharmaceutical Importer · Poland · Nutritional Supplements Focus · $1.9M Total Trade · DGFT Verified

Organosyn Limited Llc is a pharmaceutical importer based in Poland with a total trade value of $1.9M across 5 products in 3 therapeutic categories. Based on 85 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Organosyn Limited Llc sources from 1 verified Indian supplier, with Organosyn Life Sciences Private Limited accounting for 100.0% of imports.

Organosyn Limited Llc — Import Portfolio & Supplier Network

Organosyn Limited Llc import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Organosyn Limited Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Organosyn Life Sciences Private Limited	$14.7M	705	100.0%

Organosyn Limited Llc sources from 1 verified Indian supplier across 246 distinct formulations. The sourcing is highly concentrated — Organosyn Life Sciences Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Protechon ,coated tablets in container	$667.3K	31
Combigrip hot sip, powder for oral	$586.6K	36
Flamidase gel 40 GM in laminate tube	$552.2K	12
Mebsyn retard , capsules 200MG no 30	$463.1K	13
Protechon,coated tablets in container	$442.7K	22
Voritab-200, film coated tablets 200 MG	$378.7K	15
Flamidase gel 100 GM in laminate tube	$364.9K	9
Zotek -400, film coated tablets, 400 MG	$361.7K	16
Flamidase, film coated tablets no30	$342.3K	7
Combigrip , tablets no 80 paracetamol	$323.5K	14
Clatinol kit for peroral use no 42 (6?7)	$307.2K	8
Protechon fast?, film coated tablets	$302.4K	10
Protechon? ,coated tablets in	$300.7K	10
Combigrip dexa, tablets no80	$300.2K	8
Protechon ,coated tablets in	$300.0K	6

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Clotrimazole	Antifungals	$812.9K	33	0.9%	12
2	Chondroitin	Nutritional Supplements	$419.3K	14	8.2%	4
3	Glucosamine	Nutritional Supplements	$419.3K	14	3.2%	7
4	Dextromethorphan	Respiratory & OTC	$159.8K	8	1.1%	16
5	Ambroxol	Respiratory & OTC	$125.0K	16	0.8%	15

Organosyn Limited Llc imports 5 pharmaceutical products across 3 categories into Poland totaling $1.9M.

Organosyn Limited Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Organosyn Limited Llc is a pharmaceutical importer based in Poland, specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in Poland's pharmaceutical distribution network, ensuring the availability of a diverse range of medicinal products to meet the country's healthcare needs. While specific details about its parent company are not publicly disclosed, Organosyn Limited Llc's operations are integral to the Polish pharmaceutical supply chain.

2Distribution Network

Organosyn Limited Llc's distribution network encompasses multiple warehouse locations strategically situated across Poland to facilitate efficient logistics and timely delivery of pharmaceutical products. The company's logistics capabilities are robust, enabling it to manage a significant volume of imports and maintain a steady supply of medications throughout the country. While the primary focus is on the Polish market, Organosyn Limited Llc also engages in international trade, importing pharmaceutical products from countries such as India.

3Industry Role

Within Poland's pharmaceutical supply chain, Organosyn Limited Llc functions as a primary wholesaler and importer. The company sources a variety of pharmaceutical products from international suppliers, including a notable partnership with Organosyn Life Sciences Private Limited in India. By importing finished pharmaceutical formulations, Organosyn Limited Llc ensures that a wide array of medications is available to meet the diverse healthcare needs of the Polish population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Organosyn Limited Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Organosyn Limited Llc exhibits a high degree of sourcing concentration, with a significant portion of its pharmaceutical imports originating from a single supplier: Organosyn Life Sciences Private Limited. This single-source dependency may present risks, such as supply chain disruptions or pricing volatility. However, the consistent volume of shipments and the substantial total import value suggest a stable and mutually beneficial relationship between Organosyn Limited Llc and its Indian supplier. The company's strategic choice to concentrate sourcing from one supplier likely aims to streamline operations and ensure product consistency.

2Supply Chain Resilience

The resilience of Organosyn Limited Llc's Indian supply chain is a critical factor in maintaining a steady supply of pharmaceutical products. The company's reliance on a single supplier, Organosyn Life Sciences Private Limited, indicates a deep integration and trust in this partnership. While this concentration may expose the company to risks associated with supply chain disruptions, the long-standing and consistent nature of the relationship suggests a robust and reliable supply chain. The diversity of formulations imported further enhances supply chain resilience by mitigating the impact of potential disruptions in any single product line.

Strategic Implications

Importing Pharmaceuticals into Poland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Poland

1Regulatory Authority & Framework

In Poland, the Chief Pharmaceutical Inspectorate (Główny Inspektorat Farmaceutyczny) is the primary regulatory authority overseeing the manufacturing and import of medicinal products. The Pharmaceutical Law Act serves as the cornerstone of the legal framework governing pharmaceutical imports, establishing the requirements for marketing authorization and the conditions under which medicinal products can be imported into Poland. The President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) is responsible for granting marketing authorizations, ensuring that imported products meet the necessary safety, efficacy, and quality standards. The Chief Pharmaceutical Inspectorate supervises compliance with these regulations, conducting inspections and issuing decisions related to the import and distribution of medicinal products. (archiwum.gif.gov.pl)

2Import Licensing & GMP

Importing medicinal products into Poland requires obtaining an import license from the Chief Pharmaceutical Inspectorate. This license is granted based on the Pharmaceutical Law Act and ensures that the importing entity complies with all regulatory requirements. Additionally, imported products must adhere to Good Manufacturing Practice (GMP) standards. The Chief Pharmaceutical Inspectorate evaluates the compliance of manufacturing conditions with GMP requirements, including inspections of manufacturing sites in third countries. Recognized GMP certifications include EU GMP, WHO GMP, and PIC/S, all of which are accepted in Poland. (archiwum.gif.gov.pl)

Organosyn Limited Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Organosyn Limited Llc's focus on importing products in the Nutritional Supplements, Antifungals, and Respiratory & OTC categories aligns with prevalent health concerns and market demand in Poland. The significant import value of Clotrimazole and Chondroitin indicates a strong market demand for antifungal treatments and joint health supplements. The inclusion of Respiratory & OTC products suggests a strategic response to seasonal health issues and the growing preference for over-the-counter remedies. This product strategy enables Organosyn Limited Llc to cater to a broad spectrum of healthcare needs, positioning itself as a versatile supplier in the Polish pharmaceutical market.

2Sourcing Profile

Organosyn Limited Llc's sourcing strategy is characterized by a focus on generic drugs, particularly in the therapeutic areas of antifungals, nutritional supplements, and respiratory treatments. The company's preference for finished pharmaceutical formulations allows for efficient market entry and distribution within Poland. India's well-established pharmaceutical manufacturing sector, known for its adherence to international quality standards, makes it a preferred sourcing destination for Organosyn Limited Llc. This sourcing approach ensures a consistent supply of high-quality products at competitive prices, aligning with the company's mission to provide affordable healthcare solutions.

Market Positioning

Seller's Guide — How to Become a Supplier to Organosyn Limited Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Organosyn Limited Llc, particularly in the therapeutic areas where the company has a significant import volume. The existing gaps in Organosyn Limited Llc's current sourcing, such as the absence of alternative suppliers for certain products, present avenues for diversification and risk mitigation. Indian exporters can explore these opportunities by demonstrating compliance with Polish regulatory standards, offering competitive pricing, and ensuring consistent product quality.

2Requirements & Qualifications

Indian exporters aiming to supply Organosyn Limited Llc and the Polish market must obtain marketing authorizations from the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB). Products must comply with Good Manufacturing Practice (GMP) standards, with certifications such as EU GMP, WHO GMP, or PIC/S being recognized in Poland. Additionally, labeling must be in Polish and adhere to the requirements set forth by Polish regulations. Ensuring these qualifications will facilitate market entry and establish a foundation for successful collaboration.

How to Approach

Frequently Asked Questions — Organosyn Limited Llc

What products does Organosyn Limited Llc import from India?

Organosyn Limited Llc imports 5 pharmaceutical products across 3 categories. Top imports: Clotrimazole ($812.9K), Chondroitin ($419.3K), Glucosamine ($419.3K), Dextromethorphan ($159.8K), Ambroxol ($125.0K).

Who supplies pharmaceuticals to Organosyn Limited Llc from India?

Organosyn Limited Llc sources from 1 verified Indian suppliers. The primary supplier is Organosyn Life Sciences Private Limited (100.0% of imports, $14.7M).

What is Organosyn Limited Llc's total pharmaceutical import value?

Organosyn Limited Llc's total pharmaceutical import value from India is $1.9M, based on 85 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Organosyn Limited Llc focus on?

Organosyn Limited Llc imports across 3 categories. The largest: Nutritional Supplements (43.3%), Antifungals (42.0%), Respiratory & OTC (14.7%).

Get Full Organosyn Limited Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.